Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > RedChip Visibility Issues Research Update On BioForce Nanosciences Holdings, Inc.

Abstract:
RedChip Visibility, a division of RedChip Companies, Inc., announced that it has issued a second quarter research update on BioForce Nanosciences Holdings, Inc. (OTCBB:BFNH).

RedChip Visibility Issues Research Update On BioForce Nanosciences Holdings, Inc.

Orlando, FL | Posted on October 26th, 2007

Tony Telan, RedChip Research Analyst, wrote in the report:

"BioForce Nanosciences, Inc.(OTCBB:BFNH), a developer of nanotechnology instruments, consumables, and applications for the life sciences industry, announced the completion of a financing transaction valued up to $3.45 million. The transaction entailed sales to an institutional investor of Series A 8% Convertible Preferred Stock at $0.50 per share and a series of warrants with exercise prices ranging from $0.50 to $1.25 per share. Notably, the transaction is structured at a fixed price and therefore protects the interests of current shareholders.

"In summary, we continue to believe BFNH offers a compelling investment opportunity for those seeking exposure to micro-cap nanotechnology equities. With a current market cap of less than $16 million, BFHN is undervalued given the expected trajectory of near-term revenue growth and the large ultimate market potential of the Company's product offering. Using sales of AFMs as a proxy for market size and assuming approximately 8,000 AFM sales to date yields a potential market of $1.3 billion (8,000 systems x $160,000 per system) for the NeN system, or $800 million assuming a lower sales target (5,000 systems). Note this analysis conservatively does not include 1) follow on sales of consumables (e.g. the "ink cartridge" and "paper"), 2) potential price increases for high throughput product enhancements or 3) intellectual property related to its ViriChip and Chip-on-a-Tip product development initiatives."

To receive a complimentary copy of the RedChip Visibility research update for BFNH, please visit:

http://www.redchip.com/visibility/about.asp?page=requestbfnh_q2_2007&from=newsbfnh10262007

####

About RedChip Companies, Inc.
RedChip Companies is an international small-cap research and financial public relations firm with offices in Beijing and Orlando and affiliates in New York and San Diego. RedChip delivers measurable results for its clients through its extensive international market expertise as well as its comprehensive platform of products: RedChip Research, Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences held throughout the United States, RedChip Radio, and RedChip TV.

To learn more about RedChip's products and services please visit:

http://www.redchip.com/visibility/services.asp

Disclosures

The analysts contributing to this report do not hold any shares of BFNH. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. RedChip certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report. Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change. BFNH is a client of RedChip Visibility, a division of RedChip Companies. BFNH paid RedChip Visibility $32,400 for the RedChip Visibility Research Program, which includes this report. RedChip Visibility has been contracted by BFNH to increase investor awareness of BFNH to the small-cap equity community. These services may include investor conferences and digital and print distribution of BFNH investor related materials. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip was hired by the Company and receives a monthly fee of $5,500 and warrants to purchase 80,000 shares of the Company's common stock.

For more information, please click here

Contacts:
BioForce Nanosciences
515-233-8333


RedChip Companies, Inc.
Investor Relations:
1-800-RedChip ext. 127

Copyright © PrimeNewswire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Graphene Flagship start-up Bedimensional closes a second €10 million investment round February 10th, 2023

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

Investments/IPO's/Splits

Daikin Industries becomes OCSiAl shareholder July 27th, 2021

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

Nanomedicine

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery: NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery September 13th, 2024

Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024

Nanobody inhibits metastasis of breast tumor cells to lung in mice: “In the present study we describe the development of an inhibitory nanobody directed against an extracellular epitope present in the native V-ATPase c subunit.” August 16th, 2024

Announcements

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024

Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers/Posters

Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024

Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Tools

New material to make next generation of electronics faster and more efficient With the increase of new technology and artificial intelligence, the demand for efficient and powerful semiconductors continues to grow November 8th, 2024

Turning up the signal November 8th, 2024

Quantum researchers cause controlled ‘wobble’ in the nucleus of a single atom September 13th, 2024

Faster than one pixel at a time – new imaging method for neutral atomic beam microscopes developed by Swansea researchers August 16th, 2024

Nanobiotechnology

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery: NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery September 13th, 2024

Nanobody inhibits metastasis of breast tumor cells to lung in mice: “In the present study we describe the development of an inhibitory nanobody directed against an extracellular epitope present in the native V-ATPase c subunit.” August 16th, 2024

The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project